Lv75
4560 积分 2023-06-12 加入
Once-Weekly Ribupatide for Weight Loss in Adults in China With Overweight or Obesity
3天前
已完结
Efficacy and safety of once‐weekly semaglutide versus once‐daily sitagliptin as add‐on to metformin in patients with type 2 diabetes in SUSTAIN China : A 30‐week, double‐blind, phase 3a, randomized trial
30天前
已完结
Mazdutide versus placebo in Chinese adults with type 2 diabetes
1个月前
已完结
Mazdutide versus placebo in Chinese adults with type 2 diabetes
1个月前
已完结
Once-weekly IcoSema versus once-daily insulin glargine U100 in type 2 diabetes management (COMBINE 4): an open-label, multicentre, treat-to-target, randomised, phase 3b trial
2个月前
已完结
Once-weekly IcoSema versus once-daily insulin glargine U100 in type 2 diabetes management (COMBINE 4): an open-label, multicentre, treat-to-target, randomised, phase 3b trial
2个月前
已完结
Once-Weekly Insulin Icodec vs Once-Daily Insulin Glargine U100 in Combination with Bolus Insulin in Individuals with Type 2 Diabetes on Basal-Bolus Regimens (ONWARDS 4)
2个月前
已关闭
Once-Weekly Insulin Icodec vs Once-Daily Insulin Glargine U100 in Combination with Bolus Insulin in Individuals with Type 2 Diabetes on Basal-Bolus Regimens (ONWARDS 4)
2个月前
已关闭
Tirzepatide monotherapy in Chinese patients with early type 2 diabetes: A randomized, double-blind, placebo-controlled phase 3 trial (SURPASS-CN-MONO)
3个月前
已完结
Tirzepatide monotherapy in Chinese patients with early type 2 diabetes: A randomized, double-blind, placebo-controlled phase 3 trial (SURPASS-CN-MONO)
3个月前
已完结